Advances in targeted therapy for malignant lymphoma

Advances in targeted therapy for malignant lymphoma.

Full text not available from this repository.
Item Type: Review
Status: Published
Official URL:
Journal or Publication Title: Signal Transduction and Targeted Therapy
Volume: 5
Number: 1
Date: 2020
Divisions: Gene and Stem Cell Therapy
Depositing User: General Admin
Identification Number: 10.1038/s41392-020-0113-2
ISSN: 2059-3635
Date Deposited: 22 Dec 2020 03:40

The incidence of lymphoma has gradually increased over previous decades, and it ranks among the ten most prevalent cancers worldwide. With the development of targeted therapeutic strategies, though a subset of lymphoma patients has become curable, the treatment of refractory and relapsed diseases remains challenging. Many efforts have been made to explore new targets and to develop corresponding therapies. In addition to novel antibodies targeting surface antigens and small molecular inhibitors targeting oncogenic signaling pathways and tumor suppressors, immune checkpoint inhibitors and chimeric antigen receptor T-cells have been rapidly developed to target the tumor microenvironment. Although these targeted agents have shown great success in treating lymphoma patients, adverse events should be noted. The selection of the most suitable candidates, optimal dosage, and effective combinations warrant further investigation. In this review, we systematically outlined the advances in targeted therapy for malignant lymphoma, providing a clinical rationale for mechanism-based lymphoma treatment in the era of precision medicine.

Wang, Li
Qin, Wei
Huo, Yu-Jia
Li, Xiao
Shi, Qing
Rasko, John E. J.
Janin, Anne
Zhao, Wei-Li
Last Modified: 05 Jan 2021 21:52

Actions (login required)

View Item View Item